Tyr967

Site Information
sPLGsGAyRSVGEWL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 15229321

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	bone cancer ( 1 ) , cervical cancer ( 3 ) , cervical adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 2 ) , HeLa S3 (cervical) ( 3 ) , Saos-2 (bone cell) ( 1 )

Upstream Regulation
Treatments:	nocodazole ( 3 )

References
1	Bai Y, et al. (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-11 22461510 Curated Info
2	Moritz A (2010) CST Curation Set: 9059; Year: 2010; Biosample/Treatment: cell line, HeLa/Peroxide; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
3	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info